gastroduodenal ulcer. Peptic ulcer, site unspecified
Conditions
Interventions
Intervention 1: " intervention group: We will give pantoprazole tablet 40 mg every 12 hours for 72 hours and then will continue with same dose for 4 weeks. Intervention 2: "Control group: We will giv
Treatment - Drugs
" intervention group: We will give pantoprazole tablet 40 mg every 12 hours for 72 hours and then will continue with same dose for 4 weeks
"Control group: We will give IV pantoprazole 40 mg as stat dose and then 8 mgr per hours for 72 hours .we will continue pantoprazole tablet 40 mgr twice daily for 4 weeks.
Sponsors
Vice Chancellor for research of Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Every person with upper gastrointestinal bleeding due to peptic ulcer, which is the new log endoscopic bleeding (bleeding ulcer in the jet, the vessel featured in the wound bed, the wound with mild persistent bleeding, and ulcers with adherent clots in bed ). Exclusion criteria: patients with upper GI bleeding with other causes, such as bleeding from esophageal or gastric varices or cancer and patients with clean base peptic ulcer without active bleeding.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endoscopic evidence of bleeding from gastric or duodenal ulcer. Timepoint: ?Before intervention, 72 hours an 4 weeks after intervention. Method of measurement: Endoscopy before intervention, check of blood pressureand hemoglobin 72 hours and 4 weeks after intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of units of blood required. Timepoint: 8 weeks after intervention. Method of measurement: Questionnaire.;Need for surgery. Timepoint: Upto 4 weeks after intervention. Method of measurement: Questionnaire.;Days of hospitalization. Timepoint: Upto 4 weeks after intervention. Method of measurement: Questionnaire.;The need for re-endoscopy because of bleeding. Timepoint: Upto 4 weeks after intervention. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Mohammad Valizadeh Toosi
Inflammatory Diseases of Upper Gastrointestinal Tract Research Center
Outcome results
None listed